Time Is Of The Essence As Teva Considers European Assets Bids

 
• By Kevin Grogan

Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.

Judges
Teva is looking to raise $1bn in the sale of non-core assets in Europe • Source: Shutterstock

More from Deals

More from Business